516 followers
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Research volume 22, Article number: 4 (2020) Research article, Open Access, 10 January 2020 https://t.co/AeKPpKt08b https://t.co/FRNq